This open, prospective, noncomparative study evaluated clinical and metabolic aspects of
the use of a contraceptive combination of ethinyl estradiol (30 μg) and gestodene (75 μg) …

Objective: To compare ovulation inhibition and ovarian activity with 21-day and 24-day
regimens of a low-dose combined oral contraceptive (COC) containing 60 μg of gestodene …

The pharmacokinetics of gestodene (GEST) and ethinylestradiol (EE 2) were determined in
14 healthy women (age 18 to 32 years) during a treatment period of three months with a new …

The efficacy and safety of the low dose monophasic oral contraceptive (OC) combination
containing 30 µg of ethinylestradiol (EE) and 2.0 mg of dienogest (DNG)(EE/DNG) was …

The changes in haemostasis during oral contraception are related to the ethinylestradiol
dose present in the formulation taken by the patient. An open, randomized longitudinal study …

The efficacy and acceptability of two third generation oral contraceptives in Thai women
were evaluated in a prospective, open, group-comparative, randomized, multicenter trial of …

Single doses of ethynylestradiol (30 μg) were given alone and in combination with either
gestodene (75 μg) or desogestrel (150 μg) to 10 healthy female volunteers. The doses of …

Objectives This study aims to assess vaginal bleeding patterns and cycle control of oral
contraceptives containing estetrol (E4) combined with either drospirenone (DRSP) or …

Spotting and bleeding are among the most common side effects associated with oral
contraceptive (OC) use and their occurrence is a prime determinant of whether a new user …

The new low-dose combination oral contraceptive (OC) containing 75 micrograms of the
new progestogen gestodene (GTD) plus 30 micrograms ethinyl estradiol (EE) was clinically …